IN8bio Inc. Common Stock (INAB)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary of confusing a low price with a bargain, and IN8bio is a good example. It is a clinical-stage biopharmaceutical company with 18 employees, developing gamma-delta T cell candidates; its lead asset, INB-400, is in a Phase 2 trial for newly diagnosed glioblastoma. No revenue appears in the filed figures. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$4.8 million and diluted EPS was -$0.25. Fiscal Q1 2026, ended 2026-03-31, showed -$5.1 million and -$0.26. Full-year fiscal 2025 had -$19.4 million and -$4.44; fiscal 2024 had -$30.4 million and -$17.05; fiscal 2023 had -$30.0 million and -$1.00. The moat, if any, depends on trial data and regulatory approval, not earning power today. Financial health is fragile: trailing free cash flow was -$14.6 million, a FairStock-calculated FCF yield of -125.5% against the $11.6 million market cap at the 2026-10-13 close. FairStock also shows a Piotroski score of 1/9 and Altman Z-score of -6.76. Debt is modest, with D/E of 0.12, but FairStock-calculated ROE is -111.11% and ROCE is -58.37%. At the 2026-10-13 close of $1.18, FairStock's P/B of 0.63 and P/E of -0.91 are not Graham-style safety; they reflect losses and cash consumption. Growth cannot be judged without revenue. The Lynch category is none because it lost money in each of the last four years. The key variables are cash runway, dilution, and trial data.

In plain English: IN8bio is a very small company testing new cell treatments for cancer and autoimmune diseases. It has no reported revenue and has lost money for years, so the business looks weak and fragile. At $1.18 on 2026-10-13, it looks cheap compared with the value of its assets minus liabilities, but because it burns cash heavily, that low price may reflect high risk rather than a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer